Axogen, INC 8-K filings

Axogen, Inc. announced robust second quarter 2026 financial results, exceeding expectations and leading to an upward revision of full-year revenue guidance.

Axogen Inc. announced first quarter 2026 financial results, with revenue up 26.6% year-over-year to $61.5 million, and raised its full-year revenue guidance to at least 20% growth, targeting $270 million.

Axogen, Inc. announced robust fourth quarter and full-year 2025 financial results, highlighted by significant revenue growth, FDA approval for Avance, and positive 2026 financial guidance.

Axogen, Inc. announced the pricing of an upsized public offering of 4 million common shares at $31.00 each, aiming to raise $124 million to repay its term loan facility and for general corporate purposes.

Axogen, Inc. announced preliminary unaudited fourth quarter and full-year 2025 financial results, reporting significant revenue growth and the FDA approval of its Avance biologic.

Axogen, Inc. announced a 7% base salary increase and a higher target bonus for CFO Lindsey Hartley, alongside a new two-year post-employment non-competition agreement.

Axogen, Inc. announced FDA approval of its Biologics License Application for Avance, transitioning the nerve allograft to a biologic classification and strengthening its regulatory position.

Axogen, Inc. reported strong third-quarter 2025 financial results with a 23.5% revenue increase and raised its full-year revenue guidance to at least 19% growth.

Axogen's Biologics License Application for Avance Nerve Graft faces a three-month extension of its FDA review timeline due to a major amendment.

Axogen, Inc. reported strong second quarter 2025 financial results with an 18.3% revenue increase and a return to net income, prompting a raise in full-year revenue guidance.

Axogen, Inc. announced that its shareholders approved all five proposals at the 2025 annual meeting, including the re-election of directors, ratification of auditors, executive compensation, and an increase in shares for the long-term incentive plan.

Axogen reports a 17.4% increase in first quarter revenue and announces Lindsey Hartley as the new CFO, succeeding Nir Naor.

Axogen, Inc. anticipates minimal impact from recently announced US tariffs and potential retaliatory actions due to its primarily domestic sales and manufacturing operations.

Axogen announces its strategic plan for 2025-2028, focusing on driving revenue growth, achieving positive cash flow, and establishing its nerve repair solutions as the standard of care.

Axogen, Inc. announced positive fourth quarter and full-year 2024 financial results, highlighting revenue growth, improved margins, and progress towards BLA approval for Avance Nerve Graft.

Axogen reports a 15.1% increase in fourth-quarter revenue and a 17.8% increase in full-year 2024 revenue, driven by solid performance across its product portfolio.

Axogen announced a 17.9% revenue increase for the third quarter of 2024, alongside progress on its Biologics License Application (BLA) for Avance Nerve Graft.

Axogen has completed the submission of its Biologics License Application to the FDA for its Avance Nerve Graft, marking a significant step in its regulatory transition.

Axogen has announced the appointment of Michael Dale as its new CEO and Paul Thomas as the Chairman of the Board, effective August 9, 2024, marking a significant leadership transition for the company.

Axogen, Inc. announced a 25.6% increase in second-quarter revenue and progress on its Biologics License Application for Avance Nerve Graft.

Axogen Inc. filed an amendment to its 8-K report to correct typographical errors related to the results of its annual shareholder meeting held on June 5, 2024.

Axogen's annual shareholder meeting saw the election of nine directors, ratification of auditors, and approval of executive compensation, while a proposal to increase shares for the long-term incentive plan was not approved.

Axogen, Inc. announced a 12.9% increase in revenue for the first quarter of 2024, alongside improved gross margins and reduced net losses, signaling progress towards profitability.

Axogen's Chief Research and Development Officer, Angelo Scopelianos, has resigned and will transition into a consulting role through the end of 2024.

Axogen released an updated corporate presentation on March 5, 2024, showcasing strong revenue growth, clinical data, and strategic initiatives in nerve repair.

Axogen reported an 18.7% increase in fourth-quarter revenue and a 14.7% increase in full-year revenue for 2023, driven by growth in both trauma and non-trauma procedures.